Neoadjuvant treatment of esophageal cancer

Table 6 Randomized controlled trials of neoadjuvant and adjuvant chemoradiotherapy vs surgery alone for esophageal cancer

Studies (yr)	Histology	Treatment	n	MS (mo)	5-yr OS (%)	P
Nygaard et al[51], 19921	SCC	BC + 35 Gy	47	8	173	NS
		Surgery	41	7	93
Apinop et al[75], 19941	SCC	CF + 20 Gy	35	10	24	NS
		Surgery	34	7	10
Le Prise et al[76], 19941	SCC	CF + 20 Gy	41	10	193	NS
		Surgery	45	11	143
Walsh et al[77], 19961	AC	CF + 40 Gy	58	16	323	< 0.05
		Surgery	55	11	63
Bosset et al[33], 19971	SCC	C + 37 Gy	143	19	7	NS
		Surgery	139	19	9
Urba et al[78], 20011	AC/SCC	CFV + 45 Gy	50	17	20	NS
		Surgery	50	18	10
Lee et al[79], 20041	SCC	CF + 45 Gy	51	28	493	NS
		Surgery	50	27	413
Burmeister et al[80], 20051	AC/SCC	CF + 35 Gy	128	22	17	NS
		Surgery	128	19	13
Tepper et al[81], 20081	AC/SCC	CF + 50.4 Gy	30	54	39	< 0.01
		Surgery	26	21	16
Macdonald et al[82], 20012	AC4	F + 45 Gy	281	36	503	< 0.01
		Surgery	275	27	413

¹Neoadjuvant chemoradiotherapy;

²Adjuvant chemoradiotherapy;

³3-year OS;

⁴20% of patients enrolled had AC of the gastroesophageal junction (GEJ). MS: Median survival; SCC: Squamous cell carcinoma; AC: Adenocarcinoma; B: Bleomycin; C: Cisplatin; F: Fluorouracil; V: Vindesine; NS: Not significant; OS: Overall survival.